Links from our newsletters

You are interested in the studies we introduced in our latest newsletters?
Here we linked them for you.



"20 Years Immunoassay Expertise"


Chimera Biotec Celebrates!

Starting in 2000, with our proprietary Immuno-PCR platform Imperacer®, Chimera has specialized in ultra sensitive GLP/GCP bioanalytical support for all phases of drug discovery.

Get your assay! Get excellence!

                    ♦  GLP / GCP test facility
                    ♦  Non-regulated, preclinical & clinical support
                    ♦  Compliant with FDA & EMA guidances
                    ♦  Ultra sensitive immunoassay platforms
                    ♦  Assay feasibility
                    ♦  Full assay devevlopment services
                    ♦  Kit-based services




Ever wondered how
companies come up
with their names?

This is our story:


A Chimera is a mixed being in Greek mythology:

“She was of divine stock, not of men, in the fore part a lion, in the hinder a serpent, and in the midst a goat, breathing forth in terrible wise the might of blazing fire.” (Homer, Iliad 6,180 ff.)

Our Chimera is the Immuno-PCR platform Imperacer®, in which antibody-DNA conjugates combine ELISA-type immunoassay setup with exponential PCR read-out:

“She was of ultra sensitivity, in the fore part antibody, in the hinder DNA, enabling forth in outstanding sensitive wise the might of groundbreaking science.”


Bring together Imperacer®, AnySource® and Chimera´s 20 years of experience in beyond ELISA sensitive immunoassays, combining ultra sensitivity, broad assay range and minimal sample volume requirement.

That´s why Chimera Biotec: We provide optimal assay development for your target and bioanalysis under GLP/GCP regulations.



"Bispecific T Cell Engager - Their Role in Immuno-Oncology"



Here, Ma et al. (2020) describe T cell engagers (TCEs) binding to the tumor marker CEA (serum carcinoembryonic antigen) on cancer cells
and CD3 on T cells in the tumor compartment to form bivalent TCE ternary complex (biTTC).

They use a quantitative systems pharmacology (QPS) model to explore TCE efficiency, identify potential biomarkers
and can even predict patient-specific response to TCE treatment.





We routinely develop and validate ultra sensitive PK assays for GLP/GCP regulated bioanalytical sample testing support of bispecific antibody-based therapies, such as TCRs, for treatment of various malignancies.

Chimera´s AnySource® sample dilution minimizes matrix effects, enabling therapeutic antibodies target detection in the presence of ~ 1,000,000-fold excess of endogenous antibodies.


We offer complete service packages (PK/PD, Immunogenicity, Biomarker) across multiple platforms.



"Neurodegenerative Diseases - Bioanalytical Solutions"



Here, Yoo et al. (2020) suggest soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.

While increased levels in Aβ*56 alone can indicate mild AD, additionally increased AβO levels give hint to a moderate stage.

This suggests soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.



To address the low oral bioavailability and side effects of levodopa, Arisoy et al. (2020) used nano-sized drug carriers for nose to brain delivery.

The levodopa-coated biocompatible nanoparticles prolonged release up to 9h and improved locomotor activity in Parkinson´s Diesease model in mice.




Please feel free to contact Chimera Biotec’s team of dedicated scientists for more in-depth information. We are looking forward to provide you with the immunoassay to exceed your highest expectations.